Application of Megavoltage Imaging to Reduce Artifact After Seed Implants

William St Clair10 enrolled

Overview

This is a non-randomized study to evaluate the utility of MVCT as a quality assurance measure in patients treated with interstitial permanent seed implants for low and intermediate risk prostate cancer. All patients will received the same standard of care treatment but will receive an additinoal CT image of the prostate.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Prostate Cancer

Interventions

MVCTRADIATION

Patients will receive an additional MVCT scan at their one month follow up visit.

Eligibility

Sex: MALEMin age: 50 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: Male 50-80 years of age Eligible for interstitial brachytherapy implants Exclusion Criteria: \-

Locations (1)

Markey Cancer Center

Lexington, Kentucky, United States

Outcomes

Primary Outcomes

Change in prostate volume measured in cm^3

Change in prostate volume measured with trans-rectal ultrasound at baseline versus prostate volume measured with KVCT and MVCT.

Time frame: One month post implant

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.